Clinical Trials | May 20, 2024
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi approved by USFDA
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
It is the first autotaxin inhibitor to be investigated in cancer patients
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
This turn valve is considered revolutionary because it supports back-to-back drug infusion through the same device
Subscribe To Our Newsletter & Stay Updated
